clinical trial · NCT03425539
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
Fabry DiseaseLucerastatPlacebo
brief summary
This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.
started
Jun 21, 2018
primary completion
Aug 17, 2021
completion
Sep 2, 2021
last updated
Aug 9, 2024
detailed description
The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.
official title
A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol